Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences
Stifel 2022 Healthcare Conference
- Date & Time:
Tuesday, November 15, 2022 at10:55 a.m. ET - Format: Company presentation and one-on-one meetings
- Date & Time:
Wednesday, November 16, 2022 at11:30 a.m. GMT - Format: Company presentation and one-on-one meetings
A live webcast of each presentation will be available on the Investors section of the
About
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contacts
Investors:
[email protected]
Media:
SVP, Corporate Affairs
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-investor-conferences-301672184.html
SOURCE